clinical chemistry system-dimension rxl ישראל - עברית - Ministry of Health

clinical chemistry system-dimension rxl

גאמידור דיאגנוסטיקה בע"מ - צוות טכני - מכשיר לבדיקות כימיה מעבדתיות

Clinical neurophysiology diagnostic equipment ישראל - עברית - Ministry of Health

clinical neurophysiology diagnostic equipment

אורגיל ציוד רפואי בע"מ - רופא - imq 0051 אבחון נוירופיזיולוגי, ע"פ הוראות היצרן שאושרו ע"י הגוף המאשר

אמווסי ישראל - עברית - Ministry of Health

אמווסי

amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

ניופוגן 30 MU בקבוקונים ישראל - עברית - Ministry of Health

ניופוגן 30 mu בקבוקונים

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן MU 48 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 48 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן  MU 30 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 30 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

אופטלגין זריקות ישראל - עברית - Ministry of Health

אופטלגין זריקות

teva pharmaceutical indust.ltd - dipyrone 1 g / 2 ml - solution for injection - metamizole sodium - as an analgesic: optalgin injection, by intravenous administration, is indicated for the relief of severe and acute pain when oral treatment is not feasible or suitable, as in post-traumatic or post-surgical pain, biliary or renal colic, and pain associated with malignant diseases. intravenous administration of dipyrone should be carried out slowly over a period of at least 5 minutes, followed by reasonable clinical observation. intramuscular administration of dipyrone for relief of pain is not recommended.however, if medical circumstances require such administration, all due precautions should be exercised to permit reasonable clinical observation. as an antipyretic: optalgin injection by intramuscular administration is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision.

יירבוי 5 מגמל ישראל - עברית - Ministry of Health

יירבוי 5 מגמל

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

רביף 22 מקג ישראל - עברית - Ministry of Health

רביף 22 מקג

merck serono ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

ברקלוד 1 מ"ג ישראל - עברית - Ministry of Health

ברקלוד 1 מ"ג

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.